CSL Limited (ASX:CSL)
Australia · Delayed Price · Currency is AUD 171.48
-4.18 (-2.38%)
At close: Dec 24, 2025
CSL Limited Employees
CSL Limited had 29,904 employees as of June 30, 2025. The number of employees decreased by 2,794 or -8.54% compared to the previous year.
Employees
29,904
Change (1Y)
-2,794
Growth (1Y)
-8.54%
Revenue / Employee
793.56K AUD
Profits / Employee
153.12K AUD
Market Cap
82.72B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 29,904 | -2,794 | -8.54% |
| Jun 30, 2024 | 32,698 | 633 | 1.97% |
| Jun 30, 2023 | 32,065 | 2,065 | 6.88% |
| Jun 30, 2022 | 30,000 | 5,000 | 20.00% |
| Jun 30, 2021 | 25,000 | -2,000 | -7.41% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ramsay Health Care | 90,000 |
| Sonic Healthcare | 45,000 |
| Ansell | 15,000 |
| Regis Healthcare | 12,000 |
| Cochlear | 5,500 |
| Telix Pharmaceuticals | 234 |
| Pro Medicus | 132 |
| 4DMedical | 124 |
CSL Limited News
- 19 days ago - Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years - PRNewsWire
- 5 weeks ago - CSL Limited (CSLLY) Commits $1.5B to Expand U.S. Operations - GuruFocus
- 5 weeks ago - Australian biotech CSL announces $1.5B investment in the U.S. - Seeking Alpha
- 7 weeks ago - CSL Limited (CSLLY) Analyst/Investor Day Prepared Remarks Transcript - Seeking Alpha
- 2 months ago - CSL Limited (CSLLY) Shareholder/Analyst Call Transcript - Seeking Alpha
- 2 months ago - CSL Limited (CSLLY) Shareholder/Analyst Call - Slideshow - Seeking Alpha
- 2 months ago - CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) - PRNewsWire
- 2 months ago - Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines - PRNewsWire